Biopharma Tax Strategy Demystified: A Q&A With Ernst & Young
Executive Summary
Several of this year’s biggest biopharma M&A deals provide significant tax benefits. “The Pink Sheet” brushes up on how multinational companies are managing tax considerations and examines more closely the core taxation issues for the industry.